(Albany, United States) As per DelveInsight’s assessment, globally, the Inflammatory Pain pipeline constitutes 3+ key companies continuously working towards developing 3+ Inflammatory Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Inflammatory Pain pipeline report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Inflammatory Pain NDA approvals (if any), and product development activities comprising the technology, Inflammatory Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Inflammatory Pain pipeline treatment landscape of the report, click here @ Inflammatory Pain Pipeline Outlook

 

Key Takeaways from the Inflammatory Pain Pipeline Report

• DelveInsight’s Inflammatory Pain Pipeline analysis depicts a robust space with 3+ active players working to develop 3+ pipeline treatment therapies.
• The leading Inflammatory Pain Companies in the market include Norpharma, Parexel, Pfizer, GE Healthcare, Centrexion Therapeutics and others.
• Promising Inflammatory Pain Pipeline Therapies in the various stages of development include Ibuprofen, Diclofenac, Methyl-salicylate / Menthol, PF-04531083, Jincaopian Tablets high dose, Fentanyl-TTS, Duloxetine, GSK3858279 IV, and others.
• On February 2023, Regeneron Pharmaceuticals announced a study of phase 3 clinical trials for Fasinumab, Diclofenac, and Celecoxib. The primary objective of the study is to evaluate the efficacy of fasinumab compared to placebo, when administered for up to 24 weeks in patients with pain due to osteoarthritis (OA) of the knee or hip.
• On May 2023, Standford University announced a study of phase 1 clinical trials for [18F]FDG. The investigators are studying the ability of PET/MR imaging (using the PET tracer [18F]FDG) to objectively identify and characterize pain generators in patients suffering from chronic pain.
• On June 2023, Hudson Medical announced a study of phase 1 clinical trias for Root.Health Dietary Supplement. This is a research study to evaluate the effectiveness of daily supplementation with Root.Health, a plant-based dietary supplement, on reducing levels of 11 abnormal urine biomarkers associated with chronic pain. Biomarkers are molecules found in blood, tissues, or other body fluids (such as urine) that indicate normal or abnormal processes.

 

Inflammatory Pain Overview

Inflammatory pain is associated with inflammatory response due to harmful stimuli. The damaged tissue because of an external stimuli is responsible for the activation of inflammatory mediators which leads to potentiation of pain.

 

To explore more information on the latest breakthroughs in the Inflammatory Pain Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/inflammatory-pain-pipeline-insight

 

Inflammatory Pain Emerging Drugs Profile

• CNTX 6970: Centrexion Therapeutics

 

Inflammatory Pain Pipeline Therapeutics Assessment

There are approx. 3+ key companies which are developing the therapies for Inflammatory Pain. The Inflammatory Pain companies which have their Inflammatory Pain drug candidates in the most advanced stage, i.e. phase II include, Centrexion Therapeutics.

 

Request a sample and discover the recent advances in Inflammatory Pain Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/inflammatory-pain-pipeline-insight

 

Inflammatory Pain Drugs and Companies

• Ibuprofen: Futura Medical Developments Ltd
• Diclofenac: Parexel
• PF-04531083: Pfizer
• Jincaopian Tablets high dose: Beijing Konruns Pharmaceutical Co., Ltd
• Duloxetine: Eli lilly and Company

 

Inflammatory Pain Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Inflammatory Pain Therapeutics Market include-

Norpharma, Parexel, Pfizer, GE Healthcare, Centrexion Therapeutics and others.

 

Dive deep into rich insights for drugs for Inflammatory Pain Pipeline, click here for Inflammatory Pain Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/inflammatory-pain-pipeline-insight

 

Scope of the Inflammatory Pain Pipeline Report

• Coverage- Global
• Inflammatory Pain Companies- Norpharma, Parexel, Pfizer, GE Healthcare, Centrexion Therapeutics and others.
• Inflammatory Pain Pipeline Therapies- Ibuprofen, Diclofenac, Methyl-salicylate / Menthol, PF-04531083, Jincaopian Tablets high dose, Fentanyl-TTS, Duloxetine, GSK3858279 IV, and others
• Inflammatory Pain Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Inflammatory Pain Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/inflammatory-pain-pipeline-insight

 

Table of Content

1. Introduction
2. Executive Summary
3. Inflammatory Pain: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Inflammatory Pain – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Inflammatory Pain Collaboration Deals
9. Mid Stage Products (Phase II)
10. CNTX 6970: Centrexion Therapeutics
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. AAV-AQP1: Kadmon Gene Therapy
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Inflammatory Pain Key Companies
17. Inflammatory Pain Key Products
18. Inflammatory Pain- Unmet Needs
19. Inflammatory Pain- Market Drivers and Barriers
20. Inflammatory Pain- Future Perspectives and Conclusion
21. Inflammatory Pain Analyst Views
22. Inflammatory Pain Key Companies
23. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services